title: [Medicoeconomic aspects of benign prostatic hyperplasia medical treatment].
abstract: BACKGROUND
  The medicoeconomic issues of drug management of benign prostatic hyperplasia (BPH) are essential due to the aging population and the increasing number of therapeutic options. It is thus essential to assess the cost-effectiveness in order to define the most appropriate therapeutic strategies economically. The objective of this work was to conduct a literature review on the medicoeconomic studies on the drug therapy of BPH.
  
  
  METHODS
  After analyzing the literature, 43 articles were found and 9 were selected for their relevance.
  
  
  RESULTS
  Based on Markov models, we observed that: combination therapy and combined treatments (alphablockers and inhibitors of 5-alpha reductase [5ARI]) seemed to have the best cost-effectiveness. Then came the alphablockers, less expensive but exposing to a greater risk of progression and to the necessity of surgical treatments. Then came the 5ARI monotherapy and finally simple monitoring.
  
  
  CONCLUSIONS
  The Markov models are imperfect tools, and resources invested in care depend on both the economic model and the value that individuals and society give to efficiency and cost.
authors.affiliation: Service d'urologie, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France. Electronic address: souhil.lebdai@gmail.com.
authors.forename: S
authors.initials: S
authors.lastname: Lebdai
authors.affiliation: Service d'urologie, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France.
authors.forename: A R
authors.initials: AR
authors.lastname: Azzouzi
authors.affiliation: Service d'urologie, CHU Cochin, 75014 Paris, France.
authors.forename: N-B
authors.initials: NB
authors.lastname: Delongchamps
authors.affiliation: Service d'urologie, hôpital Bichat - Claude-Bernard, groupe des hôpitaux universitaires Paris-Nord-Val-de-Seine, université Denis-Diderot Paris-VII, 75018 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Benchikh
authors.affiliation: Service d'urologie, CHU Mondor, 75000 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Campeggi
authors.affiliation: Service d'urologie, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France.
authors.forename: J-N
authors.initials: JN
authors.lastname: Cornu
authors.affiliation: Service d'urologie, clinique Turin, 75008 Paris, France.
authors.forename: O
authors.initials: O
authors.lastname: Dumonceau
authors.affiliation: Clinique mutualiste Beausoleil, 34070 Montpellier, France.
authors.forename: A
authors.initials: A
authors.lastname: Faix
authors.affiliation: Service d'urologie, centre hospitalier Aix-en-Provence, 13616 Aix-en-Provence, France.
authors.forename: M
authors.initials: M
authors.lastname: Fourmarier
authors.affiliation: Service d'urologie, CHU de Tours, 37044 Tours, France.
authors.forename: O
authors.initials: O
authors.lastname: Haillot
authors.affiliation: Service d'urologie, clinique Turin, 75008 Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Lukacs
authors.affiliation: Service d'urologie, hôpital Pontchaillou, CHU de Rennes, 35000 Rennes, France.
authors.forename: R
authors.initials: R
authors.lastname: Mathieu
authors.affiliation: Service d'urologie, clinique Pasteur, 31300 Toulouse, France.
authors.forename: V
authors.initials: V
authors.lastname: Misrai
authors.affiliation: Service d'urologie, université Bordeaux-Segalen, CHU de Bordeaux, 33076 Bordeaux, France.
authors.forename: G
authors.initials: G
authors.lastname: Robert
authors.affiliation: Service d'urologie, CHU Mondor, 75000 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: de La Taille
authors.affiliation: Service de chirurgie urologique, CHU de Limoges, 87042 Limoges, France.
authors.forename: A
authors.initials: A
authors.lastname: Descazeaud
mesh_terms: D004359:Drug Therapy, Combination; D017048:Health Care Costs; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000191:economics*
keywords: Benign prostatic hyperplasia; Cost-effectiveness; Coût–efficacité; Drug; Hypertrophie bénigne de la prostate; Incremental cost-effectiveness ratio; Lower urinary tract symptoms; Symptômes du bas appareil urinaire; Traitement médicamenteux